WNK1 and acute myeloid leukemia: The recent development of small molecule inhibitors to WNK kinases20,21 prompted us to interrogate the suitability of WNK1, another top dropout kinase hit from our screen (Supplementary Fig. 1a, b), as a potential target for AML.